2:1 for new genomic techniques
At the end of December, genetic engineering sceptics celebrated that the Council of Agriculture Ministers narrowly failed to reach a qualified...
Naobios and Sumagen partner to develop HIV vaccine
Under the contract, Naobios SAS will provide bioprocess development and GMP production of clinical batches of a virus-based HIV vaccine candidate...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Novo Nordisk to acquire Cardior Pharmaceuticals
The take-over agreement includes Cardior’s lead compound CDR132L, currently in Phase II clinical development for the treatment of heart failure....
Spanish Ferrer SA pays €122.5m for ALS candidate
Ferrer inked a €112.5m deal with the US-headquartered AI drug discovery specialist Verge Genomics to commercialise the PIKfyve (1...
Flindr Therapeutics BV secures €20m Series A financing
The Series A financing was led by V-Bio Ventures and an international syndicate that includes Johnson & Johnson Innovation – JJDC, Inc., QBIC...
Gut bacteria seed autoimmunity-inducers
A unique mechanism, reported by an Irish-French research team underscores an emerging theme in microbiome research: that disruptions to gut bacteria...